- Home
- Products
- Customized FluoroAb™
- LY6E
- Anti-LY6E MAb (Clone 1)-iFluor® 488 Succinimidyl Ester
Anti-LY6E MAb (Clone 1)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS9618)
This product is comprised of an Anti-LY6E antibody (Clone 1) labeled with iFluor® 488 Succinimidyl Ester. iFluor® 488 Succinimidyl Ester is a Green-fluorescent dye and it's excitation/emission is 403/427 nm.
- TARGET
- ANTIBODY
- DYE
- Name
- LY6E
- Overview
- Anti-LY6E antibody (Clone 1)
- Species Reactivity
- Human
- Name
- iFluor® 488 Succinimidyl Ester
- Color
- Green
- Excitation⁄Emission (nm)
- 491/516
- Detection method
- Fluorescent
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for WJY0-LS9618. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-305 | Anti-LY6E-Mc-VC-PABC-MMAE ADC | MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE (Monomethyl auristatin E) |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-EGFR MAb (Clone 2)-iFluor® 532 Succinimidyl Ester (CAT#: WJY0-LS12508)
- Anti-IL6 MAb (Clone 15)-iFluor® 555 Succinimidyl Ester (CAT#: WJY0-LS16735)
- Anti-PDCD1 MAb (Clone 12)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS10687)
- Anti-CD79B MAb (Clone 14)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS854)
- Anti-TNFRSF17 MAb (Clone 9)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS3454)
- Anti-CD4 MAb (Clone 35)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS4244)
- Anti-MSTN MAb (Clone 4)-iFluor® 532 Succinimidyl Ester (CAT#: WJY0-LS12971)
- Anti-ITGAL MAb (Clone 4)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS2911)
- Anti-CD3E MAb (Clone 11)-iFluor® 460 Succinimidyl Ester (CAT#: WJY0-LS8818)
- Crenezumab-iFluor 546 (CAT#: ADC-FL-113)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
